| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
60,190,000 |
| Market
Cap: |
554.95(M) |
| Last
Volume: |
1,702,056 |
Avg
Vol: |
1,688,350 |
| 52
Week Range: |
$4.11 - $13.46 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Anavex Life Sciences is a clinical stage biopharmaceutical company engaged in the development of therapeutics by applying medicine to central nervous system (CNS) diseases. Co.'s primary compound, ANAVEX®2-73, is being developed to treat Alzheimer's disease, Parkinson's disease and other CNS diseases, including rare diseases, such as Rett syndrome. Co.'s proprietary SIGMACEPTOR™ Discovery Platform produced small molecule drug candidates with certain modes of action, based on its understanding of sigma receptors. Compounds that have been subjects of Co.'s research include the following: ANAVEX®3-71, ANAVEX®1-41, ANAVEX®1066, and ANAVEX®1037.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
7,835 |
| Total Buy Value |
$0 |
$0 |
$0 |
$32,919 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
73,380 |
| Total Sell Value |
$0 |
$0 |
$0 |
$374,972 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Thomas Steffen |
Director |
– • – |
2025-06-05 |
4 |
D |
$7.75 |
$87,955 |
D/D |
(11,349) |
43,651 |
|
- |
|
| Thomas Steffen |
Director |
– • – |
2025-06-05 |
4 |
OE |
$1.76 |
$88,000 |
D/D |
50,000 |
55,000 |
|
- |
|
| Donhauser Peter D.o. |
Director |
– • – |
2024-06-14 |
4 |
B |
$3.64 |
$10,319 |
D/D |
2,835 |
5,000 |
2.39 |
41% |
|
| Thomas Steffen |
Director |
– • – |
2024-05-15 |
4 |
B |
$4.52 |
$22,600 |
D/D |
5,000 |
5,000 |
2.39 |
21% |
|
| Missling Christopher U |
President and CEO |
• • – |
2024-03-28 |
4 |
S |
$5.11 |
$374,972 |
D/D |
(73,380) |
1,250,210 |
|
-30% |
|
| Missling Christopher U |
President and CEO |
• • – |
2024-03-28 |
4 |
OE |
$1.32 |
$96,862 |
D/D |
73,380 |
1,323,590 |
|
- |
|
| Missling Christopher U |
President and CEO |
• • – |
2023-06-29 |
4 |
OE |
$1.60 |
$371,200 |
D/D |
232,000 |
1,250,210 |
|
- |
|
| Missling Christopher U |
President and CEO |
• • – |
2023-06-28 |
4 |
S |
$7.98 |
$2,139,310 |
D/D |
(268,000) |
1,018,210 |
|
24% |
|
| Missling Christopher U |
President and CEO |
• • – |
2023-06-28 |
4 |
OE |
$1.60 |
$428,800 |
D/D |
268,000 |
1,286,210 |
|
- |
|
| Skarpelos Athanasios |
Director |
– • – |
2022-05-25 |
4 |
S |
$9.06 |
$453,000 |
D/D |
(50,000) |
1,306,458 |
|
- |
|
| Skarpelos Athanasios |
Director |
– • – |
2022-05-25 |
4 |
OE |
$0.92 |
$46,000 |
D/D |
50,000 |
1,356,458 |
|
- |
|
| Boenisch Sandra |
PFO and Treasurer |
• – – |
2021-06-29 |
4 |
S |
$26.53 |
$4,422,445 |
D/D |
(166,696) |
22,963 |
|
- |
|
| Boenisch Sandra |
PFO and Treasurer |
• – – |
2021-06-29 |
4 |
OE |
$3.28 |
$699,163 |
D/D |
166,696 |
189,659 |
|
- |
|
| Missling Christopher U |
President and CEO |
• • – |
2021-06-29 |
4 |
S |
$26.00 |
$1,342,120 |
D/D |
(51,620) |
1,018,210 |
|
- |
|
| Missling Christopher U |
President and CEO |
• • – |
2021-06-29 |
4 |
OE |
$1.32 |
$68,138 |
D/D |
51,620 |
1,069,830 |
|
- |
|
| Favus Elliot |
Director |
– • – |
2021-05-21 |
4 |
S |
$11.70 |
$1,696,283 |
D/D |
(145,000) |
0 |
|
- |
|
| Favus Elliot |
Director |
– • – |
2021-05-21 |
4 |
OE |
$0.92 |
$280,820 |
D/D |
145,000 |
145,000 |
|
- |
|
| Donhauser Peter D.o. |
Director |
– • – |
2021-05-17 |
4 |
B |
$10.93 |
$10,930 |
D/D |
1,000 |
2,165 |
2.39 |
- |
|
| Favus Elliot |
Director |
– • – |
2021-02-24 |
4 |
S |
$12.66 |
$1,841,855 |
D/D |
(145,500) |
0 |
|
- |
|
| Favus Elliot |
Director |
– • – |
2021-02-24 |
4 |
OE |
$2.58 |
$445,390 |
D/D |
145,500 |
145,000 |
|
- |
|
| Donhauser Peter D.o. |
Director |
– • – |
2021-02-19 |
4 |
B |
$12.62 |
$14,760 |
D/D |
1,165 |
1,165 |
2.39 |
- |
|
| Missling Christopher U |
President and CEO |
• • – |
2018-03-07 |
4 |
AB |
$2.92 |
$3,971 |
D/D |
1,360 |
1,018,210 |
|
- |
|
| Missling Christopher U |
President and CEO |
• • – |
2018-03-06 |
4 |
AB |
$2.73 |
$3,959 |
D/D |
1,450 |
1,016,850 |
|
- |
|
| Missling Christopher U |
President and CEO |
• • – |
2018-03-05 |
4 |
AB |
$2.63 |
$3,945 |
D/D |
1,500 |
1,015,400 |
|
- |
|
| Missling Christopher U |
Director, President & CEO |
• • – |
2018-03-02 |
4 |
AB |
$2.41 |
$3,977 |
D/D |
1,650 |
1,013,900 |
|
- |
|
53 Records found
|
|
Page 1 of 3 |
|
|
0.26 (2.74%) 
